Why GSBR-1290’s phase 2 progress matters for Structure Therapeutics (GPCR)

Structure Therapeutics (GPCR) is back in focus as its oral obesity candidate GSBR-1290 advances through phase 2 trials. This is a key clinical stage that can materially influence sentiment around the company’s pipeline and valuation.

At a share price of US$74.92, Structure Therapeutics has had a mixed short term pattern, with a 1 day share price return of 2.34% but a 7 day share price return decline of 15.30%. Its 1 year total shareholder return of 173.43% and 3 year total shareholder return of 225.74% highlight how strongly sentiment has shifted around its obesity pipeline as GSBR-1290 moves through phase 2.

If GSBR-1290’s progress has you thinking more broadly about weight loss and metabolic treatments, it could be worth checking out 26 healthcare AI stocks as a starting point for other potential ideas in this theme.

With the stock up very sharply over the past year and analysts’ average price target sitting above the current US$74.92 level, the real question is whether GPCR still offers upside or if the market is already pricing in future growth.

Preferred price to book multiple of 6.7x: Is it justified?

At a last close of $74.92, Structure Therapeutics trades on a P/B of 6.7x, which is high relative to much of the US Pharmaceuticals sector but still sits well below its closer peer group.

The P/B ratio compares the company’s market value to its book value. At 6.7x you are paying several times more than the underlying net assets on the balance sheet. For a clinical stage biopharma with no revenue and a net loss of $210.685m, that typically reflects how strongly the market values the pipeline and future potential rather than current financials.

Relative to the wider US Pharmaceuticals industry average P/B of 2.4x, GPCR’s 6.7x multiple is materially richer, which suggests investors are willing to pay up for its obesity and metabolic programs. However, compared to a peer average P/B of 40.4x, the same 6.7x looks far more restrained, indicating that the market is still pricing GPCR at a discount to some of the more aggressively valued names in its closer peer set.

Result: Price to book ratio of 6.7x (OVERVALUED)

However, there are clear risks here, including GSBR-1290 failing in phase 2 or fresh safety signals that could quickly cool enthusiasm around the whole pipeline.

Build Your Own Structure Therapeutics Narrative

If you look at this and reach a different conclusion, or simply prefer to test the numbers yourself, you can quickly build your own view using Do it your way.

A great starting point for your Structure Therapeutics research is our analysis highlighting 2 key rewards and 4 important warning signs that could impact your investment decision.

Looking for more investment ideas?

If GSBR-1290 has sharpened your interest in opportunities, do not stop here. Broaden your watchlist now so you are not chasing ideas after they move.

• Target stability first and let growth potential come second by scanning our 82 resilient stocks with low risk scores that focus on resilience when conditions change.
• Hunt for quality at a sensible entry point by using the 52 high quality undervalued stocks to spot companies trading below what their fundamentals may justify.
• Build a watchlist of potential future standouts with the screener containing 24 high quality undiscovered gems, before they attract wider market attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.